BMY vs NVS
Bristol Myers Squibb Co. and Novartis AG, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | BMY | NVS |
|---|---|---|
| Revenue | $48.2B | $54.5B |
| Net income | $7.1B | $14.0B |
| Gross margin | 71.1% | 78.8% |
| Net margin | 14.6% | 25.6% |
| Return on equity | 40.5% | 31.0% |
| Diluted EPS | $3.46 | $7.15 |
| Dividend / share | $2.49 | · |
| Payout ratio | 71.5% | · |
| Free cash flow | $12.8B | $17.6B |
| Equity | $18.5B | $46.1B |
| Net debt / equity | 1.87× | 0.37× |
| Current ratio | 1.26× | 1.12× |
| Revenue CAGR 5y | 2.5% | 2.3% |
| Profit CAGR 5y | · | 11.6% |
BMY and NVS book revenue within 15% of each other, and NVS keeps more of each dollar of revenue as profit (25.6% against 14.6%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | BMY | NVS |
|---|---|---|
| FY2025 | $48.2B | $54.5B |
| FY2024 | $48.3B | $50.3B |
| FY2023 | $45.0B | $45.4B |
| FY2022 | $46.2B | $42.2B |
| FY2021 | $46.4B | $42.8B |
| FY2020 | $42.5B | $48.7B |
| FY2019 | $26.1B | $47.5B |
| FY2018 | $22.6B | $44.8B |
| FY2017 | $20.8B | $42.4B |
| FY2016 | $19.4B | $48.5B |
Bottom line
| Fiscal year | BMY | NVS |
|---|---|---|
| FY2025 | $7.1B | $14.0B |
| FY2024 | $-8.9B | $11.9B |
| FY2023 | $8.0B | $14.8B |
| FY2022 | $6.3B | $7.0B |
| FY2021 | $7.0B | $24.0B |
| FY2020 | $-9.0B | $8.1B |
| FY2019 | $3.4B | $11.7B |
| FY2018 | $4.9B | $12.6B |
| FY2017 | $1.0B | $7.7B |
| FY2016 | $4.5B | $6.7B |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$6,338,000,000 | NVS |
| FY2024 | −$2,017,000,000 | NVS |
| FY2023 | −$434,000,000 | NVS |
| FY2022 | +$3,953,000,000 | BMY |
| FY2021 | +$3,604,000,000 | BMY |
| FY2020 | −$6,141,000,000 | NVS |
| FY2019 | −$21,353,000,000 | NVS |
| FY2018 | −$22,272,000,000 | NVS |
| FY2017 | −$21,605,000,000 | NVS |
| FY2016 | −$29,091,000,000 | NVS |
The higher-revenue side has changed between BMY and NVS over this period. The gap has narrowed since the earliest year compared.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −11.0 pp | NVS |
| FY2024 | −42.2 pp | NVS |
| FY2023 | −14.8 pp | NVS |
| FY2022 | −2.7 pp | NVS |
| FY2021 | −41.0 pp | NVS |
| FY2020 | −37.7 pp | NVS |
| FY2019 | −11.5 pp | NVS |
| FY2018 | −6.2 pp | NVS |
| FY2017 | −13.5 pp | NVS |
| FY2016 | +9.4 pp | BMY |
The higher net margin has changed hands between BMY and NVS over this period.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BMY's net margin has been more volatile than NVS's over the 10 comparable fiscal years — 15.0 percentage points of standard deviation against 11.6.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between BMY and NVS over these 10 fiscal years — BMY led in 1 and NVS in 9.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BMY's return on equity has been more volatile than NVS's over the 10 comparable fiscal years — 24.0 percentage points of standard deviation against 9.6.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between BMY and NVS over these 10 fiscal years — BMY led in 4 and NVS in 6.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.